Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Teligene US
United States
- Ownership
- Private
- Development stage
- Other
01
Overview
Lead program (sutetinib maleate targeting EGFR mutations in NSCLC) is in Phase 3. Multiple other assets in Phase 1/2 and Phase 2. Preclinical and early clinical data show promise for addressing treatment-resistant and brain-metastatic tumors, particularly in oncology indications with high unmet need.
- Therapeutic areas
- Oncology
- Modalities
- Small molecule
- Industry
- Biotech
02
Partnerships
Suzhong PharmaChina Construction Bank (CCB Capital)GTJA Investment GroupIDG CapitalLoyal Valley CapitalShenzhen CapitalHuitianfu Capital
Beyond the preview
Go deeper on Teligene US.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Teligene US.